In plain terms: SGLT2 inhibitors (empagliflozin, dapagliflozin) has strong evidence from human clinical trials. The benefit shown in those trials is reduction of cardiovascular death, heart-failure hospitalization and kidney-failure progression, replicated across three separate randomized populations. no trial has tested them for longevity in healthy adults if that describes your situation.
SGLT2 inhibitors (empagliflozin, dapagliflozin)
The evidence as the record states it
Zinman et al., EMPA-REG OUTCOME (New England Journal of Medicine, 2015; PMID 26378978): randomized, placebo-controlled, empagliflozin 10 mg or 25 mg daily added to standard care in patients with type 2 diabetes at high cardiovascular risk, with cardiovascular death, non-fatal myocardial infarction and non-fatal stroke as the primary composite. McMurray et al., DAPA-HF (New England Journal of Medicine, 2019; PMID 31535829): phase 3 randomized trial of dapagliflozin 10 mg daily in patients with heart failure and reduced ejection fraction, with and without diabetes. Heerspink et al., DAPA-CKD (New England Journal of Medicine, 2020; PMID 32970396): 4,304 participants with chronic kidney disease, with and without type 2 diabetes. Three independent randomized trials, three different populations, all on hard clinical outcomes, which is the replicated-hard-outcome route to Grade A. The same caution that applies to semaglutide applies here and is the more important half of this record: the A is earned in people who already have cardiovascular, cardiac or renal disease. Nothing in this evidence says an SGLT2 inhibitor extends life in a healthy adult, and no trial has asked.
Why Grade A and not higher
Grade A requires a hard clinical endpoint or objectively measured functional outcome, independently replicated across at least two trials. SGLT2 inhibitors (empagliflozin, dapagliflozin) meets that standard based on the trials cited above. A downgrade to Grade B would follow if replication attempts produced null results, if the effect size proved substantially smaller in a broader population, or if the studied dose proved impractical to sustain.
What this grade covers and what it does not
What would move this grade
A null result in a well-powered independent replication trial, or evidence that the effect does not hold at a practically sustainable dose, would prompt downgrade to Grade B.
How this was studied
Form: Empagliflozin or dapagliflozin tablets once daily, added to standard care, versus placebo · Dose: Empagliflozin 10 mg or 25 mg (EMPA-REG OUTCOME); dapagliflozin 10 mg (DAPA-HF and DAPA-CKD) · Population: 7,020 adults with type 2 diabetes at high cardiovascular risk (EMPA-REG OUTCOME); 4,744 adults with heart failure and an ejection fraction of 40 percent or less, with or without diabetes (DAPA-HF); 4,304 adults with chronic kidney disease (DAPA-CKD) · Duration: Median 3.1 years (EMPA-REG OUTCOME); median 18.2 months (DAPA-HF); median 2.4 years (DAPA-CKD) · What is sold differs: Every trial enrolled a disease population: cardiovascular disease with type 2 diabetes, heart failure with reduced ejection fraction, or chronic kidney disease. No trial has given these drugs to healthy adults for aging.